Last reviewed · How we verify

Mesalazine(asacol 800 mg)

Tehran University of Medical Sciences · FDA-approved active Small molecule

Mesalazine(asacol 800 mg) is a 5-aminosalicylic acid (5-ASA) agent Small molecule drug developed by Tehran University of Medical Sciences. It is currently FDA-approved for Ulcerative colitis, mild to moderate, Crohn's disease, mild to moderate, Maintenance of remission in inflammatory bowel disease.

Mesalazine reduces intestinal inflammation by inhibiting prostaglandin and leukotriene production in the colon.

Mesalazine reduces intestinal inflammation by inhibiting prostaglandin and leukotriene production in the colon. Used for Ulcerative colitis (induction and maintenance of remission), Crohn's disease (colonic involvement).

At a glance

Generic nameMesalazine(asacol 800 mg)
SponsorTehran University of Medical Sciences
Drug class5-aminosalicylic acid (5-ASA) agent
TargetProstaglandin and leukotriene synthesis; nuclear factor-kappa B (NF-κB) pathway
ModalitySmall molecule
Therapeutic areaGastroenterology
PhaseFDA-approved

Mechanism of action

Mesalazine (5-aminosalicylic acid) is a topical anti-inflammatory agent that acts locally in the colon to suppress inflammatory mediators and reduce immune cell activation. It inhibits nuclear factor-kappa B (NF-κB) signaling and decreases production of pro-inflammatory cytokines, thereby reducing mucosal inflammation in inflammatory bowel disease.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Mesalazine(asacol 800 mg)

What is Mesalazine(asacol 800 mg)?

Mesalazine(asacol 800 mg) is a 5-aminosalicylic acid (5-ASA) agent drug developed by Tehran University of Medical Sciences, indicated for Ulcerative colitis, mild to moderate, Crohn's disease, mild to moderate, Maintenance of remission in inflammatory bowel disease.

How does Mesalazine(asacol 800 mg) work?

Mesalazine reduces intestinal inflammation by inhibiting prostaglandin and leukotriene production in the colon.

What is Mesalazine(asacol 800 mg) used for?

Mesalazine(asacol 800 mg) is indicated for Ulcerative colitis, mild to moderate, Crohn's disease, mild to moderate, Maintenance of remission in inflammatory bowel disease.

Who makes Mesalazine(asacol 800 mg)?

Mesalazine(asacol 800 mg) is developed and marketed by Tehran University of Medical Sciences (see full Tehran University of Medical Sciences pipeline at /company/tehran-university-of-medical-sciences).

What drug class is Mesalazine(asacol 800 mg) in?

Mesalazine(asacol 800 mg) belongs to the 5-aminosalicylic acid (5-ASA) agent class. See all 5-aminosalicylic acid (5-ASA) agent drugs at /class/5-aminosalicylic-acid-5-asa-agent.

What development phase is Mesalazine(asacol 800 mg) in?

Mesalazine(asacol 800 mg) is FDA-approved (marketed).

What are the side effects of Mesalazine(asacol 800 mg)?

Common side effects of Mesalazine(asacol 800 mg) include Headache, Abdominal pain, Diarrhea, Nausea, Rash, Nephrotoxicity (rare).

What does Mesalazine(asacol 800 mg) target?

Mesalazine(asacol 800 mg) targets Prostaglandin and leukotriene synthesis; nuclear factor-kappa B (NF-κB) pathway and is a 5-aminosalicylic acid (5-ASA) agent.

Related